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ABSTRACT
Objective: Diabetes mellitus is the main cause of Charcot neuroarthropathy and is clinically classified 
as follows: Charcot foot, acute Charcot foot (ACF) when there is inflammation, and inactive Charcot 
foot when inflammatory signs are absent. The aim of this study was to identify the risk factors for 
ACF in patients with type 2 diabetes mellitus. Materials and methods: A matched case-control study 
was conducted to assess the factors associated with acute Charcot foot from February 2000 until Sep-
tember 2012. Four controls for each case were selected 47 cases of ACF and 188 controls without ACF 
were included. Cases and controls were matched by year of initialization of treatment. Conditional 
logistic regression was used to estimate matched odds ratios (ORs) and 95% confidence intervals 
(95% CIs). Results: In multivariate analysis, patients having less than 55 years of age (adjusted OR 
= 4.10, 95% CI = 1.69 – 9.94), literate education age (adjusted OR = 3.73, 95% CI = 1.40 – 9.92), living 
alone (adjusted OR = 5.84, 95% CI = 1.49 – 22.86), previous ulceration (adjusted OR = 4.84, 95% CI = 
1.62 – 14.51) were at increased risk of ACF. However, peripheral arterial disease (adjusted OR = 0.16, 
95% CI = 0.05 – 0.52) of 6.25 (1.92 – 20.0) was a protective factor. Discussion: The results suggest 
that PCA in type 2 diabetes primarily affects patients under 55 who live alone, are literate, and have 
a prior history of ulcers, and that peripheral arterial disease is a protective factor. Arch Endocrinol Metab. 
2015;59(3):226-30
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INTRODUCTION
D iabetes mellitus is the main cause of Charcot neu-roarthropathy (CN) (1) and is clinically classi-
fied as follows: Charcot foot (CF), acute Charcot foot 
(ACF) when there is inflammation, and inactive Char-
cot foot when inflammatory signs are absent (2).
It reduces the patients’ quality of life and leads to 
motor disability, loss of limbs, early retirement, and 
dea th (3,4). The incidence of CF varies from 1.2 to 8.5 
per 1,000 diabetic people per year (5), and its preva-
lence from 0.1% in the overall population of individuals 
with type 2 diabetes to 12.9% among the patients who 
seek diabetic foot care services (6-8).
ACF is characterized by local inflammation (9) asso-
ciated with progressive bone and cartilage fracture and 
luxation resulting in the osteoarticular disorganization 
of a neuropathic foot (8,10). The risk factors for CF are 
not yet well established (7,11,12). The identification, 
prevention, and early manipulation of risk factors might 
delay the appearance and progression of CF. 
The aim of the present study was to identify poten-
tials risk factors associated with ACF in patients with 
type 2 diabetes and foot ulcers. 
MATERIALS AND METHODS
A matched case-control study was conducted with four 
controls selected for each case. Controls were selected 
randomly from medical registers and matched to cases 
based on year of initialization of treatment. The study 
took place in the diabetic foot outpatient clinic of the 
Alcides Carneiro University Hospital (Hospital Univer-
sitário Alcides Carneiro – HUAC), which is part of the 
Federal University of Campina Grande (Universidade 
Federal de Campina Grande – UFCG), Paraíba, Brazil, 
from February 2000 to September 2012.
The inclusion criteria were the following: foot ulcers 
in individuals diagnosed with type 2 diabetes following 
the criteria of the American Diabetes Association (13). 
The exclusion criteria were the following: history 
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(14), varicose ulcers, hypertensive (Martorell) ulcers, 
leprosy, and type 1 diabetes or other types of diabetes. 
The study was approved by the HUAC Human Re-
search Ethics Committee. The participants signed an 
informed consent form. 
Cases were defined as patients with typical clinical 
manifestations of ACF, as follows: remarkable swelling, 
heat, redness, deformities, and midfoot or ankle collap-
se that was confirmed by simple radiography (bone 
destruction, subluxation, dislocation, and deformities). 
Controls were defined as patients with type 2 diabetes 
and foot ulcers without the typical clinical manifesta-
tions of ACF. 
The patients who performed their first visit unes-
corted were referred to the HUAC social service, which 
contacted their families to inform them about the need 
for an escort. Under those circumstances, if the pa-
tients performed the second visit also unescorted, they 
were considered to be socially isolated. The weight 
and height of the participants was measured, and the 
body mass index (BMI) was calculated using Quetelet’s 
equation (BMI = body weight in kg divided by the hei-
ght in square meters). Obesity was defined as a BMI ≥ 
30 kg/m2, as recommended by the World Health Or-
ganization (15).
 The peripheral neuropathy was diagnosed based on 
the following: loss of tactile sensitivity, which was defi-
ned as a lack of perception of the monofilament con-
tact in two out of six points using a 10-g esthesiometer 
(SORRI-BAURU); loss of proprioception, which was 
defined as an insensitivity to the vibration of a 128-Hz 
tuning fork applied to the back of the hallux; loss of 
pain sensitivity, which was defined as the inability to dis-
tinguish between the contact of blunt and sharp sticks 
on the hallux; and the presence of neuropathic altera-
tions on clinical examination, including claw toes, me-
tatarsal prominence, interosseous muscle atrophy, anhi-
drosis, cracks, and corns. The patients were diagnosed 
with peripheral neuropathy when the results of two of 
the abovementioned tests were positive or when neuro-
pathic alterations were found on a clinical examination. 
The peripheral arterial circulation was assessed by 
measuring the systolic arterial pressure in all four limbs 
by means of a sphygmomanometer and DV10 vascular 
Doppler (Microem Produtos Eletrônicos Ltda.). The 
highest upper limb pressure measurement was selected 
for calculating the ankle-brachial index (ABI). ABI va-
lues from 0.91 to 1.30 were considered normal, and 
values ≤ 0.9 were considered ischemic (16).
A minimum sample size of 47 cases and 188 con-
trols was calculated (17). We assumed the prevalence of 
the 50% previous ulceration amongst cases, taking a 1:4 
ratio between cases and controls to increase the power 
of the study, with a power of 80%, at a significance level 
of 5% to detect an odds ratio (OR) of at least 3.
Statistical analysis was performed using SPSS sof-
tware package (version 17.0, IBM Corp., Armonk, NY, 
USA). Descriptive statistics were calculated for each 
variable of interest. Normal distribution of variables 
was assayed with the Kolmogorov-Smirnov normali-
ty test. Paired t-test for normally distributed variables 
was applied to compare the cases and controls, while 
Wilcoxon’s matched pairs test was used for not-normally 
distributed values. All significance tests were two-tailed 
and p < 0.05 was considered significant. Univariate and 
multivariate conditional logistic regression was used to 
compute crude and adjusted odds ratios (ORs) with 
95% confidence intervals (CIs). All variables considered 
to be significant by univariate analysis were included in 
multivariate logistic regression analysis. Variables were 
considered significant if the 95% confidence interval of 
the adjusted odds ratios did not include 1.
RESULTS
Over February 2000 to September 2012, 786 eligible 
subjects who had type 2 diabetes and foot ulcers were 
identified. Descriptive characteristics of total sample size 
selected are shown in table 1. The mean of age was 60.5 
years (sd: 12.4), 106 (45%) were female, 129 (56.1%) had 
previous ulceration and 207 (88.5%) had Neuropathy. 
The prevalence of ACF in the period of study was 6%.
Continuous characteristics of the patients with type 
2 diabetes and foot ulcers (controls) and ACF (cases) 
are compared in table 2. Between variables analyzed 
only the time of hypertension was significant difference.
Table 3  shows the univariate and multivariate 
conditional logistic analysis (matched analysis) for 
selected risk factors. In the univariate analysis, the OR: 
for males was 2.00 (95% CI 1.04 – 3.85), for less than 55 
years age was 4.57 (95% CI 2.29 – 9.10), and for pre vious 
ulceration was 3.96 (95% IC 1.75 – 8.93). Peripheral ar-
terial circulation was identified like as if it were a protec-
tive factor; the OR was 9.09 (1/0.11) times smaller (95% 
CI 2.56 – 33.33) for the absence of peripheral arterial 
circulation. Cases did not differ from controls including 
white ethnic origin, BMI ≥ 30, BMI ≥ 25 kg/m2. In the 
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Table 1. Basic socio-demographic and clinical characteristics of cases 
and controls
Variables n (%)
Sample size 235 (100)
Average age (years) 60.5 (12.4)*




















Brachial systolic pressure (mmHg) 153.2 (30.1)*
Left leg systolic pressure (mmHg) 153.1 (59.1)*
Right leg systolic pressure (mmHg) 159.7 (66.4)*
Blood glucose (mg/dL) 237.5 (117.6)*
* Mean (Standard deviation). 
Table 2. Comparative clinical characteristics of cases and controls 
Characteristics Cases Controls P-value
Age (years)ŧ 53.6 (10.2) 62.2 (12.3) 0.231
Time since diagnosis (years)ŧ 12.1 (6.8) 11.6 (7.4) 0.742
Age at diagnosis (years)ŧ 41.4 (11.3) 50.5 (13.5) 0.400
Length of hypertension (years)§ 0.8 (0 – 3) 5 (2 – 10) 0.028
BMI (kg/m2)ŧ 28.5 (6.1) 26.9 (4.4) 0.766
Blood glucose (mg/dL)ŧ 268 (119.6) 228.1 (115.8) 0.673
Creatinine (mg/dL)§ 1 (0.8 – 1.3) 1 (0.8 – 1.3) 0.419
Brachial systolic pressure (mmHg)§ 150 (130 – 160) 150 (130 – 180) 0.736
Left leg systolic pressure (mmHg)ŧ 185.8 (66.4) 149.1 (63.9) 0.722
Right leg systolic pressure (mmHg)§ 160 (140 – 190) 140 (110 – 160) 0.634
ŧ Mean (SD) and paired t-test; § Median (IQR: 25th–95th percentile) and Wilcoxon matched-pairs test.
cally significant in the model were: less than 55 years of 
age = 4.10 (95% CI 1.69 – 9.94), literate education = 
3.73 (95% CI 1.40 – 9.92), living alone = 5.84 (95% 
CI 1.49 – 22.86), previous ulceration = 4.84 (95% CI 
1.62 – 14.51) and peripheral arterial disease = 0.16 (95% 
CI 0.05 – 0.52) of 6.25 (95% CI 1.92 – 20.0) as a pro-
tective factor. After adjusting the multivariate model, a 
probability of 61% was estimated for Charcot foot for all 
characteristics in the multivariate model.
DISCUSSION 
The risk factor most strongly associated with the PC 
was social isolation. Stuck and cols., in a prospective 
study found that single men were at higher risk (18).
It was hypothesized that for those patients with dia-
betes and foot ulcers that live alone, the unrestrained 
weight bearing on an insensitive foot (19) renews the 
trauma and activates the inflammatory cascade that is 
typical of ACF. 
The past history of ulcers was the second most as-
sociated with ACF and is described in the literature as 
a risk factor (20). 
 The average age of those with cases of CF in the 
present study was 53.7 years old, thus agreeing with 
the reports of other authors that showed it affects indi-
viduals in the fifth and sixth decades of life (21,22). The 
age of the cases with less than 55 years of age was sig-
nificantly associated with ACF; however, the time since 
diagnosis of diabetes was similar, thus suggesting that 
the severity of the neuropathic complications of type 2 
diabetes was a predominant factor mainly among the 
youngest patients (20).
Although illiteracy directly impacts health outco-
mes, particularly in those with diabetes (23-26), being 
literate was not able to protect patients from ACF.
Peripheral ischemia was identified as a protective 
factor for ACF, with this being consistent with the re-
sults of other authors (12,27). The loss of sympathetic 
innervations leads to increased blood flow and decrea-
sed vascular resistance in the feet of patients with peri-
pheral neuropathy (3,28) and, in the patients with PC, 
this increase in blood flow is even greater when compa-
red to those with neuropathy alone (3,29). 
Obesity was reported as a risk factor for CF in other 
case series’, which did not occur in this population. The 
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Table 3. Results of univariate and multivariate conditional logistic regression of socio-demographic and clinical risk factors for Charcot foot




Odds ratio (95% CI)†
Multivariate analysis
Odds ratio (95% CI)†
Socio-demographics
Masculine gender 32 (68.1) 97 (51.6) 2.00 (1.04 – 3.85) –
White ethnic origin 18 (48.6) 96 (56.1) 0.74 (0.37 – 1.50) 1.47 (0,77 – 3,05)
Literate education 40 (85.1) 106 (59.6) 3.88 (1.71 – 8.81) 4.39 (1.74 – 9,53)
Living alone 9 (19.1) 20 (10.6) 5.33 (1.93 – 14.75) 4.50 (1.38 – 14.67)
Clinicals
Hypertension 22 (46.8) 123 (65.4) 0.47 (0.24 – 0.91) –
Previous ulceration 36 (80.0) 93 (50.3) 3.96 (1.75 – 8.93) 4.38 (1.72 – 11.18)
BMI ≥ 30 (kg/m2) 13 (27.7) 40 (21.3) 1.41 (0.68 – 2.95) –
BMI ≥ 25 (kg/m2) 34 (72.3) 121 (64.4) 1.44 (0.72 – 2.92) –
Peripheral arterial disease 3 (6.7) 66 (38.6) 0.11 (0.03 – 0.39) 0.14 (0.04 – 0.51)
Peripheral neuropathy£ 38 (100.0) 161 (85.6) – –
† 95% Confidence Interval; £ OR could not be included because of the absence of values  in cells of cases.
died by Stuck, which was 50%, and in this, which was 
21%, might account for this divergence (18). An asso-
ciation was also not found when the OR was calculated 
for ACF with BMI ≥ 25 kg/m2, which agrees with the 
results of other case control studies (12,20,27). 
The prevalence of ACF was 6% in the investigated 
population; whereas, in other published series, it varied 
from 0.1 to 12.9% as a function of the type of regional 
healthcare service sought, namely, general or speciali-
zed in diabetic foot care (6,7). 
The present study employed a sample of outpatients 
who spontaneously sought assistance at a public servi-
ce, and some of the results might be attributed to the 
inclusion criteria (for example, the acute cases) or even 
to the lower frequency of CF among non-white Euro-
pean populations (5,18,30).
One of the possible limitations is the criteria for the 
selection of cases and controls. As the cases were se-
lected from clinical suspicion, milder cases of PCA, in 
which there were no deformities, may have been inclu-
ded in the control group. Also, between cases, some 
patients may have developed ACF after admission into 
the diabetic foot clinic, but had lost the follow up.
It can be concluded that ACF is a significant com-
plication of type 2 diabetes, affecting socially isolated 
patients. With previous history of foot ulcers and being 
less than 55 years of age being possible risk factors for 
ACF in patients with type 2 diabetes and foot ulcers.
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